Welcome at Rejuvenate Biomed
We envision a future where people stay healthy for life.

Biology of aging

Major progress has been made in the biology of aging also known as geroscience. This has resulted in a better scientific understanding of the biological processes associated with age-related functional decline. Several mechanisms have been elucidated and drugable targets have been identified.

Prescription drug

We identify opportunities to impact the aging process by repositioning Rx products. Our portfolio currently contains 7 compounds, selected via our Pre-Clinical and Clinical platforms focusing on safety and their efficacy potential. We are preparing our lead candidate for a POC study, starting in 2020.

Lead compound RJx-01

Our lead candidate RJx-01, and first entry into market, is a combination product indicated to treat Sarcopenia. Sarcopenia is the progressive loss of skeletal muscle quality / mass and strength. It affects 2-24% of the overall population, and 50% of 80 year old. It increases the risk of physical disability, poor quality of life and death.

Latest news

Key research collaboration with Rafael de Cabo

Professor Dr. Rafael de Cabo from NIA`s Translational Gerontology Branch under a Cooperative Research & Development Agreement (CRADA) will be our collaborator in evaluating effects on the characteristics of aging, incl overall health, survival & resilience.